Biotech/pharma M&A activity definitely heating up. There is also renewed interest in neuroscience after the approval of Leqembi and other transactions. It's a massive area of unmet need.
Bristol Myers to acquire Karuna for $14Billion, page-22
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.90 |
Change
-0.110(0.52%) |
Mkt cap ! $2.681B | |||
| Open | High | Low | Value | Volume |
| $20.87 | $21.19 | $20.82 | $2.969M | 141.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $20.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.91 | 311 | 12 |
View Market Depth
| Last trade - 14.38pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.81 |
Change
-0.110 ( 0.84 %) |
||||
| Open | High | Low | Volume | ||
| $20.99 | $21.19 | $20.81 | 72018 | ||
| Last updated 14.58pm 21/05/2024 ? | |||||
| NEU (ASX) Chart |